سوق الكيمياء الطبية الأوروبية لاكتشاف الأدوية، حسب العملية ( اختيار الهدف ، التحقق من الهدف، تحديد الهدف إلى الهدف، تحسين الهدف والتحقق من صحة المرشح)، التصميم (التباين القائم على الشظايا، تصميم الدواء القائم على البنية، التخليق الموجه نحو التنوع، الكيمياء الجينومية، المنتجات الطبيعية وغيرها)، نوع الدواء (الجزيئات الصغيرة والبيولوجية)، المجال العلاجي ( علم الأورام ، علم الأعصاب، أمراض الجهاز المناعي والجهاز الهضمي ، أمراض القلب والأوعية الدموية، أمراض الجهاز الهضمي وغيرها)، المستخدم النهائي (منظمة أبحاث العقود، شركات الأدوية والتكنولوجيا الحيوية ، المعاهد الأكاديمية والبحثية وغيرها)، الدولة (ألمانيا، المملكة المتحدة، فرنسا، إيطاليا، إسبانيا، هولندا، روسيا، سويسرا، بلجيكا، تركيا، النمسا، النرويج، المجر، ليتوانيا، أيرلندا، بولندا، بقية أوروبا) اتجاهات الصناعة والتوقعات حتى عام 2029
تحليل السوق والرؤى : سوق الكيمياء الطبية الأوروبية لاكتشاف الأدوية
من المتوقع أن يحقق سوق الكيمياء الطبية الأوروبية لاكتشاف الأدوية نموًا في السوق في الفترة المتوقعة من 2022 إلى 2029. تحلل شركة Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 13.7٪ في الفترة المتوقعة من 2022 إلى 2029 ومن المتوقع أن يصل إلى 3،890.66 مليون دولار أمريكي بحلول عام 2029. إن الزيادة في الاستثمار في البحث والتطوير لاكتشاف وتطوير جزيئات الأدوية الجديدة وارتفاع الأمراض المزمنة هي المحركات الرئيسية التي دفعت الطلب على السوق في الفترة المتوقعة.
تشتمل الكيمياء الطبية لاكتشاف الأدوية على ميزات مثل الحاجة المتزايدة إلى أدوية آمنة وفعالة ستؤثر على إطلاق منتج جديد من قبل الشركات المصنعة في السوق مما يعزز الطلب عليه بالإضافة إلى زيادة الاستثمار في البحث والتطوير لاكتشاف وتطوير جزيئات الأدوية الجديدة مما يؤدي إلى نمو السوق. تجري حاليًا دراسات بحثية مختلفة ومن المتوقع أن توفر فرصًا أخرى مختلفة في سوق الكيمياء الطبية لاكتشاف الأدوية. ومع ذلك، من المتوقع أن يؤدي ارتفاع تكلفة الدواء المصنَّع ونقص المهنيين المهرة المدربين إلى كبح نمو السوق في فترة التنبؤ.
يقدم تقرير سوق الكيمياء الطبية لاكتشاف الأدوية تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق وتحليل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل، وسيساعدك فريقنا في إنشاء حل لتأثير الإيرادات لتحقيق هدفك المنشود.
Medicinal Chemistry for Drug Discovery Market Scope and Market Size
Medicinal chemistry for drug discovery market is segmented on the based on the basis of process, design, drug type, therapeutic area, end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of process, the Europe medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. In 2022, target selection segment is expected to dominate the market owing to the fact that is the first process performed for medicinal chemistry for drug discovery and approximately every drug molecule passes through this process before entering the next process.
- On the basis of design, the Europe medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products and others. In 2022, the fragment based variation segment is expected to dominate the market as this design provides with highly accurate results and majorly used for discovery of small molecule drugs.
- On the basis of drug type, the Europe medicinal chemistry for drug discovery market is segmented into small molecules and biologics. In 2022, small molecules segment is expected to dominate the market as most of the drug going under drug discovery are small molecules as compared to that of the biologic drug molecules.
- On the basis of therapeutic area, the Europe medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease and others. In 2022, oncology segment is expected to dominate the market due to increasing prevalence of different cancer types and rising demand of advanced, safe and effective therapeutic molecules.
- On the basis of end user, the Europe medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical & biotechnology companies and others. In 2022, contract research organization is expected to dominate in the market as these organizations are highly focused on drug discovery and most of the pharmaceuticals, biotechnology companies among others work in collaboration with contract research organization for accelerated drug discovery.
Medicinal Chemistry for Drug Discovery Market Country Level Analysis
The medicinal chemistry for drug discovery market is analyzed and market size information is provided on the basis of process, design, drug type, therapeutic area and end user.
The countries covered in the medicinal chemistry for drug discovery market report are the Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe.
Germany is leading the growth of the Europe medicinal chemistry for drug discovery market and target selection segment is dominating in this country due to increase in collaboration among researchers and pharmaceutical industries. France is expected to grow due to the increasing research facility institutes in France and growing pharmaceutical expenditure. U.K. is expected to grow due to growing technological advancement for drug development.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in healthcare expenditure and rising funding for research and development are boosting the market growth of medicinal chemistry for drug discovery
Medicinal chemistry for drug discovery market also provides you with detailed market analysis for every country growth in medicinal chemistry for drug discovery industry with medicinal chemistry for drug discovery sales, impact of advancement in the medicinal chemistry for drug discovery technology and changes in regulatory scenarios with their support for the medicinal chemistry for drug discovery market. The data is available for historic period 2011 to 2020.
Competitive Landscape and Medicinal Chemistry for Drug Discovery Market Share Analysis
Medicinal chemistry for drug discovery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to medicinal chemistry for drug discovery market.
بعض الشركات الكبرى التي تتعامل في الكيمياء الطبية لسوق اكتشاف الأدوية هي Eurofins Scientific، Covance Inc. (الآن جزء من LabCorp Group)، WuXi Apptec، Charles River، Thermo Fisher Scientific، Inc.، Pfizer، Inc.، Certara، USA، Malvern Panalytical Ltd (الشركة الأم Spectris PLC)، Genscript Biotech Corporation، Aurigene Pharmaceutical Services Ltd. (شركة تابعة لـ Dr. Reddy's Laboratories Ltd.)، و Selvita، من بين شركات أخرى.
يوفر العديد من اللاعبين في السوق أحدث التقنيات في الكيمياء الطبية لاكتشاف الأدوية والتي تعمل أيضًا على تسريع سوق الكيمياء الطبية لاكتشاف الأدوية.
على سبيل المثال،
- في مايو 2021، وقعت شركة تشارلز ريفر اتفاقية نهائية للاستحواذ على شركة Vigene Biosciences, Inc.، وهي منظمة رائدة مقرها الولايات المتحدة لتطوير وتصنيع عقود العلاج الجيني (CDMO). تعمل الشركة على توفير حلول توصيل الجينات القائمة على النواقل الفيروسية لتعزيز عملية اكتشاف الأدوية. وقد عززت هذه المبادرة بصمة الشركة في الكيمياء الطبية لسوق اكتشاف الأدوية
- في أغسطس 2020، أطلقت شركة Malvern Analytics خدمة Amplify Analytics التي سمحت لشركات الأدوية بتحديد المرشحين للأدوية الذين يستوفون متطلبات التوافر البيولوجي بسرعة، كما عجلت أيضًا بعملية تطوير الأدوية. وقد عززت هذه المبادرة نمو الشركة في مجال الكيمياء الطبية لسوق اكتشاف الأدوية
يعمل التعاون وإطلاق المنتج وتوسيع الأعمال والجوائز والتقدير والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعب في السوق على تعزيز سوق الشركة في الكيمياء الطبية لاكتشاف الأدوية مما يوفر أيضًا فائدة للمنظمة لتحسين عروضها لتوسع القصبات الهوائية.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PROCESS LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 POTERS FIVE FORCES
5 EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES
6.1.2 RISE IN CHRONIC DISEASES
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS
6.1.4 GROWTH IN BIOLOGICS
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES
6.2 RESTRAINTS
6.2.1 RISE IN COST OF FORMULATED DRUG
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES
6.3.2 RISE IN HEALTHCARE EXPENDITURE
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY
6.4 CHALLENGES
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES
6.4.2 STRINGENT REGULATIONS
7 IMPACT OF COVID-19 ON EUROPE MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS BY MANUFACTURERS
7.5 CONCLUSION
8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS
8.1 OVERVIEW
8.2 TARGET SELECTION
8.3 TARGET VALIDATION
8.4 HIT-TO-LEAD IDENTIFICATION
8.5 LEAD OPTIMIZATION
8.6 CANDIDATE VALIDATION
9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN
9.1 OVERVIEW
9.2 FRAGMENT-BASED VARIATION
9.3 STRUCTURE BASED DRUG DESIGN
9.4 DIVERSITY ORIENTED SYNTHESIS
9.5 CHEMOGENOMICS
9.6 NATURAL PRODUCTS
9.7 OTHERS
10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 SMALL MOLECULES
10.3 BIOLOGICS
11 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 NEUROLOGY
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES
11.5 CARDIOVASCULAR DISEASES
11.6 DIGESTIVE SYSTEM DISEASES
11.7 OTHERS
12 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER
12.1 OVERVIEW
12.2 CONTRACT RESEARCH ORGANIZATION
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 ACADEMIC AND RESEARCH INSTITUTES
12.5 OTHERS
13 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY COUNTRY
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 NETHERLANDS
13.1.7 RUSSIA
13.1.8 SWITZERLAND
13.1.9 BELGIUM
13.1.10 TURKEY
13.1.11 AUSTRIA
13.1.12 NORWAY
13.1.13 HUNGARY
13.1.14 LITHUANIA
13.1.15 IRELAND
13.1.16 POLAND
13.1.17 REST OF EUROPE
14 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 EUROFINS SCIENTIFIC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 SERVICE PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 LABCORP DRUG DEVELOPMENT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 SERVICE PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 CHARLES RIVER
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 SERVICE PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 WUXI APPTEC
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 SERVICE PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 EVOTEC SE
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 SERVICE PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 PIRAMAL PHARMA SOLUTIONS
16.6.1 COMPANY SNAPSHOT
16.6.2 SERVICE PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 THERMO FISHER SCIENTIFIC INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 SERVICE PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.7.4.1 ACQUISITION
16.8 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES)
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 SERVICE PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AURELIA BIOSCIENCES
16.9.1 COMPANY SNAPSHOT
16.9.2 SERVICE PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 BIOBLOCKS INC
16.10.1 COMPANY SNAPSHOT
16.10.2 SERVICE PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 CERTARA INC
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 SERVICE PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 DOMAINEX
16.12.1 COMPANY SNAPSHOT
16.12.2 SERVICE PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 GENSCRIPT BIOTECH
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 SERVICE PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 PFIZER INC.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 SERVICE PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 SELVITA
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 SERVICE PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.15.4.1 ACQUISITION
16.16 SPECTRIS PLC
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 SERVICE PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SYGNATURE DISCOVERY
16.17.1 COMPANY SNAPSHOT
16.17.2 SERVICE PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 TAROS CHEMICAL GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 SERVICE PORTFOLIO
16.18.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 2 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 3 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 5 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 6 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 7 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 11 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 12 GERMANY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 13 GERMANY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 14 GERMANY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 15 GERMANY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 16 GERMANY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 17 FRANCE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 18 FRANCE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 19 FRANCE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 20 FRANCE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 21 FRANCE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 22 U.K. MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 23 U.K. MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 24 U.K. MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.K. MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 26 U.K. MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 ITALY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 28 ITALY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 29 ITALY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 30 ITALY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 31 ITALY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 SPAIN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 33 SPAIN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 34 SPAIN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 35 SPAIN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 36 SPAIN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 NETHERLANDS MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 38 NETHERLANDS MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 39 NETHERLANDS MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 40 NETHERLANDS MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 41 NETHERLANDS MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 RUSSIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 43 RUSSIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 44 RUSSIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 45 RUSSIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 46 RUSSIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 SWITZERLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 48 SWITZERLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 49 SWITZERLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 50 SWITZERLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 51 SWITZERLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 BELGIUM MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 53 BELGIUM MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 54 BELGIUM MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 BELGIUM MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 56 BELGIUM MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 TURKEY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 58 TURKEY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 59 TURKEY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 60 TURKEY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 61 TURKEY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 AUSTRIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 63 AUSTRIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 64 AUSTRIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 65 AUSTRIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 66 AUSTRIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 NORWAY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 68 NORWAY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 69 NORWAY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 70 NORWAY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 71 NORWAY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 72 HUNGARY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 73 HUNGARY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 74 HUNGARY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 75 HUNGARY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 76 HUNGARY MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 LITHUANIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 78 LITHUANIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 79 LITHUANIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 80 LITHUANIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 81 LITHUANIA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 IRELAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 83 IRELAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 84 IRELAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 IRELAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 86 IRELAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 87 POLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
TABLE 88 POLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 89 POLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 90 POLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
TABLE 91 POLAND MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 REST OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 2 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: DROC ANALYSIS
FIGURE 4 MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: END USER COVERAGE GRID
FIGURE 8 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: SEGMENTATION
FIGURE 11 GROWTH IN BIOLOGICS DISCOVERY AND COLLABORATION AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRY IS EXPECTED TO DRIVE THE EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 PROCESS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET
FIGURE 14 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY PROCESS, 2021
FIGURE 15 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY PROCESS, 2020-2029 (USD MILLION)
FIGURE 16 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY PROCESS, CAGR (2022-2029)
FIGURE 17 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY PROCESS, LIFELINE CURVE
FIGURE 18 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DESIGN, 2021
FIGURE 19 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DESIGN, 2020-2029 (USD MILLION)
FIGURE 20 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DESIGN, CAGR (2022-2029)
FIGURE 21 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DESIGN, LIFELINE CURVE
FIGURE 22 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DRUG TYPE, 2021
FIGURE 23 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DRUG TYPE, 2020-2029 (USD MILLION)
FIGURE 24 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 25 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA, 2021
FIGURE 27 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA, 2020-2029 (USD MILLION)
FIGURE 28 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA, CAGR (2022-2029)
FIGURE 29 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA, LIFELINE CURVE
FIGURE 30 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY END USER, 2021
FIGURE 31 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 33 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: SNAPSHOT (2021)
FIGURE 35 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY COUNTRY (2021)
FIGURE 36 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 37 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 38 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: BY PROCESS (2022-2029)
FIGURE 39 EUROPE MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
